{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971812",
  "id": "02971812",
  "pages": 5,
  "price_sensitive": false,
  "date": "20250723",
  "time": "0953",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1vs081h8p9d.pdf",
  "summary": "### **Capital Raising Announcement Summary**  \n\n- **Structure**: Conditional Placement (subject to shareholder approval)  \n- **Total Capital Offered**: $2.5M ($0.23/share \u00d7 10,869,566 shares)  \n- **Use of Proceeds**: Funding for ACCENT/AMPLICITY trials and initiation of kRAS/OVARIAN trials for Narmafotinib (AMP 945)  \n- **Conditions**: Shareholder approval at AGM on **27 August 2025**  \n- **Issue Date**: **29 August 2025** (if approved)  \n- **Broker**: Bell Potter Securities (5.5% fee)  \n- **Other Notes**: Part of a broader $27.5M capital raise (includes Placement, SPP, Director Placement). No underwriting.  \n\n*(No material pricing/pre-emption details disclosed.)*",
  "usage": {
    "prompt_tokens": 1779,
    "completion_tokens": 183,
    "total_tokens": 1962,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T23:59:42.791855"
}